Literature DB >> 15082617

A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

N Sharma1, C Donnellan, C Preston, B Delaney, G Duckett, P Moayyedi.   

Abstract

Symptoms are an important outcome for measurement in clinical trials into gastro-oesophageal reflux disease, but the optimal approach to symptom assessment has not been formally evaluated. The authors conducted a systematic review to assess how reflux symptoms have been evaluated and how well these correlate with oesophagitis healing and relapse.

Entities:  

Mesh：

Year:  2004        PMID： 15082617      PMCID： PMC1867781          DOI： 10.1136/gut.2003.034371

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  131 in total

1.  Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial.

Authors:  J P Galmiche; G Brandstätter; M Evreux; E Hentschel; E Kerstan; P Kratochvil; W Reichel; K Schütze; J C Soule; J Vitaux
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

2.  Reflux esophagitis: assessment of therapy effects and observer variation by video documentation of endoscopy findings.

Authors:  S Gustavsson; R Bergström; C Erwall; M Krog; C E Lindholm; O Nyrén
Journal:  Scand J Gastroenterol       Date:  1987-06       Impact factor: 2.423

Review 3.  The ecological fallacy.

Authors:  S Piantadosi; D P Byar; S B Green
Journal:  Am J Epidemiol       Date:  1988-05       Impact factor: 4.897

4.  Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease.

Authors:  K Plein; J Hotz; H Wurzer; I Fumagalli; R Lühmann; A Schneider
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-04       Impact factor: 2.566

5.  Cisapride in the treatment of gastro-oesophageal reflux disease.

Authors:  C S Robertson; D F Evans; S J Ledingham; M Atkinson
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

6.  Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial.

Authors:  S Sontag; M Robinson; R W McCallum; K W Barwick; R Nardi
Journal:  Arch Intern Med       Date:  1987-08

7.  Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine.

Authors:  H Geldof; B Hazelhoff; M H Otten
Journal:  Aliment Pharmacol Ther       Date:  1993-08       Impact factor: 8.171

8.  Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study.

Authors:  W Hameeteman; D M v d Boomgaard; W Dekker; M Schrijver; I C Wesdorp; G N Tytgat
Journal:  J Clin Gastroenterol       Date:  1987-08       Impact factor: 3.062

9.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

10.  Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.

Authors:  T J Simon; R G Berlin; R Tipping; L Gilde
Journal:  Scand J Gastroenterol       Date:  1993-05       Impact factor: 2.423
View more
  4 in total

1.  Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease.

Authors:  F Cremonini; D C Ziogas; H Y Chang; E Kokkotou; J M Kelley; L Conboy; T J Kaptchuk; A J Lembo
Journal:  Aliment Pharmacol Ther       Date:  2010-03-26       Impact factor: 8.171

2.  Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Authors:  Kathleen W Wyrwich; Reema Mody; Lois M Larsen; Misun Lee; Neesha Harnam; Dennis A Revicki
Journal:  Qual Life Res       Date:  2010-02-27       Impact factor: 4.147

3.  Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.

Authors:  I M Modlin; R H Hunt; P Malfertheiner; P Moayyedi; E M Quigley; G N J Tytgat; J Tack; R C Heading; G Holtman; S F Moss
Journal:  Digestion       Date:  2009-06-17       Impact factor: 3.216

4.  Does the evidence show that prokinetic agents are effective in healing esophagitis and improving symptoms of GERD?

Authors:  Mirjam Looijer-van Langen; Sander Veldhuyzen van Zanten
Journal:  Open Med       Date:  2007-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.